> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Safety Concerns Complicate Plan to Expand Peptide Compounding
- URL: https://www.fdaweb.com/fda-safety-concerns-complicate-plan-to-expand-peptide-compounding/
- Published: 2026-10-09T22:02:55.000Z
- Updated: 2026-10-09T22:02:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General

The Trump Administration is developing a temporary policy that would allow compounding pharmacies to dispense certain unapproved peptides despite earlier FDA scientific assessments finding insufficient evidence of their safety and effectiveness, setting up a potential conflict between administration policy and the agency's scientific reviewers.

Federal officials are considering an interim enforcement-discretion policy permitting some peptides to be compounded while FDA develops permanent regulations. The proposal has not been announced, and the products that would qualify remain unclear, according to a Washington Post report earlier this week.

The potential policy would follow a July decision by FDA's Pharmacy Compounding Advisory Committee recommending that six of seven peptides under consideration be added to the agency's Section 503A Bulks List, despite FDA staff recommendations against all seven substances ([see earlier story](https://www.fdaweb.com/insufficient-data-on-7-peptides-for-potential-compounding-use-fda/)). Agency reviewers found limited clinical evidence supporting the safety and effectiveness of BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon.

The reviewers generally concluded that available evidence was insufficient to establish favorable benefit-risk profiles. FDA also identified concerns involving peptide impurities, potential immunogenicity and inadequate human safety data.

The advisory committee subsequently recommended inclusion of all seven substances except emideltide. Its recommendations were nonbinding and did not independently authorize their use in pharmacy compounding.

HHS secretary **Robert F. Kennedy Jr.** has advocated broader access to certain peptides, which have attracted increasing interest for potential applications involving wound healing, weight management, inflammation and longevity.

According to the *Post*, the Alliance for Pharmacy Compounding has urged FDA to exercise temporary enforcement discretion, allowing state-licensed pharmacies to prepare the products for patients with prescriptions. The group's chief executive, **Scott Brunner**, said the proposed approach could include enhanced patient disclosures, reporting of serious adverse events and collection of information about peptide use.

Supporters argue that regulated pharmacy compounding would provide a safer alternative to the growing market for unapproved peptides distributed through unregulated suppliers. However, FDA scientists and outside medical experts have questioned whether expanded access is appropriate without adequate clinical evidence.

The *Post* reported that the administration is considering safeguards as part of the temporary arrangement, but no final decision or implementation timetable has been disclosed.

An enforcement-discretion policy would not constitute FDA approval of the peptides or establish their safety and effectiveness. It would, however, allow certain compounding activities to proceed before FDA completes its formal regulatory review, potentially departing from the recommendations of the agency's scientific staff.